14 results about "Ileum" patented technology

A composition for use in a method of providing sustained energy release over time in a subject is described. The composition comprises or consists of microparticles comprising high glycaemic index (GI) carbohydrate contained within a gastric-resistant, ileal-sensitive, GLP-1 stimulative, non-porous carrier configured for release of the high GI carbohydrate in the ileum, wherein the composition is administered orally to the subject.

The application discloses a compound plant essential oil preparation for improving intestinal tract barrier function of laying hens and a preparation method thereof, relates to the technical field of livestock and poultry intestinal tract health regulation, and comprises microcapsule particles with a multilayer structure, which sequentially comprises a core layer, a first coating layer, an intermediate functional layer and a second coating layer; the compound plant essential oil preparation for improving intestinal tract barrier function of laying hens and the preparation method thereof are characterized in that the preparation is arranged as a multilayer microcapsule structure composed of the core layer, the first coating layer, the intermediate functional layer and the second coating layer in sequence, and the first coating layer and the second coating layer adopt enteric polymers with different pH dissolution ranges, so that the intermediate functional layer can be released first in the pH environment from the duodenum to the jejunum, and the core layer is released subsequently in the pH environment of the ileum, thereby realizing the graded and zoned release of active components of plant essential oils in the front and rear sections of the small intestine of laying hens, and matching different essential oil components with the barrier repair requirements of each section of the intestinal tract.

The application belongs to the technical field of biological medicine, and particularly relates to application of a CLIC5 gene in preparation of a drug for preventing and / or treating intestinal inflammation. The application provides application of the CLIC5 gene in preparation of a drug for preventing and / or treating intestinal inflammation, wherein a nucleotide sequence of the CLIC5 gene is shown as SEQ ID NO:1. The application finds that intestinal epithelial cell-specific knockout of the CLIC5 can reduce a serum endotoxin level, improve intestinal epithelial barrier function, increase a content of butyric acid, reduce a serum inflammatory factor level, and also reduce a gene expression level of an inflammatory factor in an ileum and a colon. The application first discloses that intestinal epithelial cell-specific knockout of the CLIC5 can effectively prevent or treat intestinal inflammation and reduce a body inflammatory factor level, thereby providing a new target and method for treating human intestinal inflammation.

This invention provides a process for preparing ileal-targeted empty capsules, relating to the field of pharmaceutical excipients technology. The process includes the following steps: preparing the following raw materials: gelatin, titanium dioxide, and sodium stearate; dissolving the gelatin in water at 60-70°C, heating and stirring, adding titanium dioxide and sodium stearate, mixing well, and allowing to stand to obtain a film-forming gel. This invention utilizes a preparation mechanism involving the mixing of water-soluble polyacrylic acid resin IV, polyacrylic acid resin III, and polyvinyl alcohol, with the remaining materials added in steps, to achieve the predetermined goal of ileal disintegration. Furthermore, based on the synergistic effect of polyacrylic acid resin III with water-soluble polyacrylic acid resin IV and polyvinyl alcohol, the drug release rate of the empty capsule is improved, allowing the drug to rapidly reach an effective concentration in the ileum and exert its therapeutic effect more effectively.

The present invention relates to a pH responsive polymer composition for the enteric coating of hard shell capsules, which composition is suitable for the delivery of pharmaceutical dosage forms, in particular microbiota, to the ileum and colon. The pH responsive polymer composition comprises at least one anionic poly (meth) acrylate copolymer, at least one glidant, at least one plasticizer, and 1 to < 6% of at least one nonionic emulsifier based on the total weight of the pH responsive polymer composition.

A gastrointestinal implant adapted to be implanted in a gastrointestinal structure such as a duodenum, a jejunum, and / or an ileum comprises a plurality of adjacent layers bonded to one another. One of more of the layers comprises at least one of a selected pore size and interpore distance, and at least one medicament is coupled to at least one medial surface of one or more layers to achieve one or more treatment goals selected from minimizing or alleviating trauma associated with implantation of the gastrointestinal sleeve, preventing or treating infection, treating eating disorders or conditions of the patient, treating one or more gastrointestinal tract structures exterior to or distal to at least a portion of the sleeve, or treating the patient's microbiome.

The application discloses a pig breed disease resistance breeding screening method based on taurine cholate metabolic markers, and belongs to the technical field of animal breeding. The application effectively screens the breeding pigs with stronger intestinal barrier function by establishing a breeding standard based on the intestinal barrier function difference, especially taking the taurine cholate level as a key index, and improves the health level and production benefit of pigs. Compared with the prior art, the ileum villus height to crypt depth ratio of the breeding pig is increased by 25.3%, the mRNA relative expression amount of ZO-1 and other tight junction proteins is increased by 32.7%, the SIgA and IgG levels are increased by 38.5%, the health level of the pig is significantly improved, and the production benefit is increased by 15.6%.

This invention relates to the field of poultry feed technology, and more particularly to a diet for determining the loss of endogenous amino acids in poultry and its application. The diet provided by this invention, by mass percentage, comprises 12-14% total amino acids, 17-22% hydrolyzed casein, 16-20% glucose, 18-21.6% amylose, and 30-37.4% amylopectin, wherein the ratio of glucose to starch is 0.30-0.40, and the ratio of amylose to amylopectin is 0.55-0.65. This invention can effectively detect the loss of endogenous amino acids in the ileum of broilers while ensuring normal weight gain and digestive physiological status, thereby improving the accuracy of calculating standard ileal amino acid digestibility, helping to reduce the waste of protein feed resources in broilers, and achieving precision nutrition.

The invention discloses a double layered delayed-release hard capsules made by double dipping, that is by two consecutive dip molding steps with the same mold pin without removing the film, provided by the first dip molding step, from the mold pin between the two dip molding steps, but dipping the mold pin with this first film on the mold pin in the second dip molding step, each dip molding step is done with a different polymer melt, providing a double layered delayed-release capsule, which passes the stomach and the jejunum and opens in the ileum.

The application discloses a strain capable of promoting vitamin B 12 absorption and improving cognitive function, and application thereof, and belongs to the technical field of biotechnology. The application provides a Paraglactobacillus paracus CCFA1525, which is preserved in the Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 67380 and a preservation date of November 18, 2025. The Paraglactobacillus paracus CCFA1525 can up-regulate the expression of key proteins in the ileum, promote the absorption of vitamin B 12 , relieve nerve damage and cognitive impairment caused by sleep deprivation, and thus plays a significant neuroprotective role. Therefore, the Paraglactobacillus paracus CCFA1525 can be used for developing products with anti-nerve damage function, and is suitable for improving cognitive impairment caused by vitamin B 12 absorption disorder, and has good functional application prospect and industrial production potential. 12 ​

The application discloses a lactobacillus gasseri for relieving salmonella typhimurium infection and application thereof, and belongs to the technical field of microorganisms. The lactobacillus gasseri CCFM1307 screened by the application has the effect of relieving inflammation caused by salmonella typhimurium infection, specifically embodied in the following aspects: significantly relieving the symptom of weight loss of an individual infected with salmonella typhimurium, significantly relieving pathological damage of an ileum and a colon of the individual infected with salmonella typhimurium, significantly reducing the level of inflammatory cytokines in intestinal tissues of the individual infected with salmonella typhimurium, significantly increasing the content of short-chain fatty acids in feces, and reducing the relative abundance of Bacteroides in feces of the individual infected with salmonella typhimurium. The lactobacillus gasseri has great application prospects in preparation of drugs for preventing, treating and / or adjuvant treating inflammation caused by salmonella typhimurium infection.

The invention discloses a composite microecological preparation and a preparation method and application thereof.The composite microecological preparation is prepared from a composite strain mainly composed of bacillus velezensis, enterococcus faecium, lactobacillus acidophilus, saccharomyces cerevisiae boulardii and clostridium butyricum, the composite strain is fermented and then forms a microcapsule structure with sodium alginate and auxiliaries, and the microcapsule structure is prepared. The probability that viable bacteria reach the tail end of the ileum can be increased, and the effects of preventing and treating lawsonia intracellularis of the pigs, adjusting the balance of intestinal flora of the pigs and improving the immunity of the pigs are achieved under the synergistic effect of probiotic substances secreted by the viable bacteria.

The invention discloses a method for determining the digestibility of mineral element nutrients in pig feed. The method comprises the following steps: selecting a test pig of which the ileum tail end and the cecum tail end are provided with T-shaped fistula, and preparing a feed containing an indicator; test periods including a pre-test period, an excrement collection period, a cecum chyme collection period and an ileum chyme collection period are set, and the test pigs are fed with the prepared feed; in the collection period, respectively collecting a feed sample, an excrement sample, a cecum chyme sample and an ileum chyme sample; measuring the content of mineral elements and the content of indicators in the feed sample, the excrement sample, the cecum chyme sample and the ileum chyme sample; and calculating the apparent digestibility of the mineral elements at different parts of the pig digestive tract according to a formula.

The application discloses application of fangchinoline in prevention and treatment of salmonella infection. The fangchinoline is an isoquinoline alkaloid and is a host-directed therapy natural compound. The application discloses that the fangchinoline has a strong effect on treatment of salmonella infection diseases in vivo and in vitro, and the effect is specifically shown as that the fangchinoline can effectively reduce the bacterial amount of intracellular infection bacteria. The fangchinoline administration can significantly reduce the pathogenic bacteria load in the liver, spleen, colon, cecum and ileum of mice, and reduce the pro-inflammatory factor level of the organism. The safety in vivo and in vitro shows that the fangchinoline has no any toxic side effect under the test dose. In addition, the fangchinoline has significant synergistic antibacterial activity in combination with fluoroquinolones, which is shown as reduction of intracellular salmonella infection bacteria number and reduction of the pathogenic bacteria load in the liver, spleen and colon of mice. The application provides a new perspective for development of a new anti-infection drug, and also provides a new idea for prevention and control of the increasingly serious salmonella infection.